Charles Schwab’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-17,873
| Closed | -$88K | – | 3619 |
|
|
2021
Q3 | $88K | Hold |
17,873
| – | – | ﹤0.01% | 3392 |
|
|
2021
Q2 | $95K | Hold |
17,873
| – | – | ﹤0.01% | 3297 |
|
|
2021
Q1 | $86K | Hold |
17,873
| – | – | ﹤0.01% | 3392 |
|
|
2020
Q4 | $78K | Hold |
17,873
| – | – | ﹤0.01% | 3332 |
|
|
2020
Q3 | $74K | Buy |
+17,873
| New | +$69.1K | ﹤0.01% | 3261 |
|
|
2020
Q2 | – | Sell |
-47,230
| Closed | -$137K | – | 3383 |
|
|
2020
Q1 | $137K | Buy |
47,230
+302
| +0.6% | +$1.35K | ﹤0.01% | 3073 |
|
|
2019
Q4 | $178K | Hold |
46,928
| – | – | ﹤0.01% | 3053 |
|
|
2019
Q3 | $241K | Hold |
46,928
| – | – | ﹤0.01% | 3013 |
|
|
2019
Q2 | $291K | Buy |
46,928
+4,381
| +10% | +$25.2K | ﹤0.01% | 3023 |
|
|
2019
Q1 | $303K | Sell |
42,547
-7,885
| -16% | -$70.9K | ﹤0.01% | 2938 |
|
|
2018
Q4 | $431K | Buy |
50,432
+1,890
| +4% | +$24.6K | ﹤0.01% | 2825 |
|
|
2018
Q3 | $972K | Sell |
48,542
-315
| -0.6% | -$7.4K | ﹤0.01% | 2640 |
|
|
2018
Q2 | $1.26M | Buy |
48,857
+13,367
| +38% | +$370K | ﹤0.01% | 2508 |
|
|
2018
Q1 | $849K | Buy |
35,490
+4,800
| +16% | +$151K | ﹤0.01% | 2567 |
|
|
2017
Q4 | $1.04M | Buy |
30,690
+3,218
| +12% | +$89.9K | ﹤0.01% | 2495 |
|
|
2017
Q3 | $582K | Hold |
27,472
| – | – | ﹤0.01% | 2676 |
|
|
2017
Q2 | $481K | Hold |
27,472
| – | – | ﹤0.01% | 2705 |
|
|
2017
Q1 | $481K | Hold |
27,472
| – | – | ﹤0.01% | 2654 |
|
|
2016
Q4 | $465K | Hold |
27,472
| – | – | ﹤0.01% | 2682 |
|
|
2016
Q3 | $451K | Hold |
27,472
| – | – | ﹤0.01% | 2645 |
|
|
2016
Q2 | $416K | Buy |
27,472
+7,000
| +34% | +$115K | ﹤0.01% | 2655 |
|
|
2016
Q1 | $297K | Buy |
20,472
+6,200
| +43% | +$104K | ﹤0.01% | 2780 |
|
|
2015
Q4 | $405K | Hold |
14,272
| – | – | ﹤0.01% | 2737 |
|
|
2015
Q3 | $239K | Hold |
14,272
| – | – | ﹤0.01% | 2910 |
|
|
2015
Q2 | $375K | Buy |
+14,272
| New | +$278K | ﹤0.01% | 2789 |
|
Charles Schwab's ADMS Position: Q4 2021 in Review
Charles Schwab sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 17,873 shares — an estimated $88K sold.
Charles Schwab first reported a position in ADMS in Q2 2015 and held it in 25 quarters. The position peaked at $1.26M in Q2 2018. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- Charles Schwab reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- Charles Schwab sold 17,873 Adamas Pharmaceuticals shares in Q4 2021, an estimated $88K.
- Charles Schwab first reported a position in Adamas Pharmaceuticals in Q2 2015 and held it in 25 quarters.
- Charles Schwab's Adamas Pharmaceuticals position peaked at $1.26M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on Charles Schwab's 13F filing for Q4 2021, filed 11 Feb 2022.